id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-001513-p7v5p036	Ekins, Sean	A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus	2014-12-12		.txt	text/plain	4756	250	56	Common features pharmacophore for EBOV actives Two papers from 2013 described compounds active as inhibitors of different EBOV strains in vitro and in vivo, namely amodiaquine and chloroquine in one study 8 , clomiphene and toremifene in another 9 . These suggest that the receptor-ligand based approach results in a general similarity across the nine structures, likely indicating the similar binding mode and importance of features for interfering with this generally hydrophobic pocket for protein-protein interactions. In silico docking of molecules in VP35 structure Redocking the 4IBI ligand in the protein resulted in an RMSD of 3.02Å, which generally indicates the difficulty of predicting orientations for compounds binding in what is a relatively hydrophobic and shallow pocket ( Figure S1 ). Pharmacophores, receptor ligand models and docking data for FDA-approved drugs inhibiting the Ebola virus, 10.5256/f1000research.5741.d38449 35 .	./cache/cord-001513-p7v5p036.txt	./txt/cord-001513-p7v5p036.txt